NDA 217369 · Biogen
Zurzuvae
Zuranolone · Oral · Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
NovelPriority reviewCDER novel approval, Aug 4, 2023: To treat postpartum depression
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 4, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
8 Phase 3, 2 recruiting
FAERS reports
1,940
306 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects [see Warnings and Precautions ( 5.1 , 5.2 )] . Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE [see Warnings and Precautions ( 5.1 )] . WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES See full prescribing information for complete boxed warning. ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage in other potentially hazardous...
What it is approved for
From the label in effect Jun 15, 2026.
ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. ( 1 )
Mechanism: The mechanism of action of zuranolone in the treatment of PPD is not fully understood but is thought to be related to its positive allosteric modulation of GABA A receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Supplement 4 · Efficacy · priority review Label
- Aug 4, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
3 products under this application
- ZURZUVAE · ZURANOLONE 30MG · CAPSULE, ORAL · Prescription
- ZURZUVAE · ZURANOLONE 20MG · CAPSULE, ORAL · Prescription
- ZURZUVAE · ZURANOLONE 25MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zuranolone" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT03864614 · 1,515 participants · Start Feb 27, 2019 · Primary completion Jun 22, 2023
Drug: SAGE-217 · For: Major Depressive Disorder
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 52 sites in all
- A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT03672175 · 581 participants · Start Nov 19, 2018 · Primary completion Sep 24, 2019
Drug: SAGE-217; Placebo · For: Major Depressive Disorder
Sites: Rogers, Arkansas; Bellflower, California; Garden Grove, California · 53 sites in all
- A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT04442490 · 543 participants · Start May 12, 2020 · Primary completion Mar 26, 2021
Drug: SAGE-217; Placebo · For: Depressive Disorder, Major
Sites: Rogers, Arkansas; Bellflower, California; Garden Grove, California · 39 sites in all
- A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT04476030 · 440 participants · Start Nov 9, 2020 · Primary completion Oct 25, 2021
Drug: SAGE-217; Matching Placebo and 5 more · For: Depressive Disorder, Major
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 51 sites in all
- A Study to Evaluate SAGE-217 in Participants With Severe Postpartum DepressionPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02978326 · 276 participants · Start Jan 4, 2017 · Primary completion Nov 15, 2018
Drug: SAGE-217 15/20 mg Oral Solution; Placebo and 1 more · For: Postpartum Depression
Sites: Little Rock, Arkansas; Beverly Hills, California; Oceanside, California · 27 sites in all
- A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT04442503 · 200 participants · Start Jun 8, 2020 · Primary completion Mar 15, 2022
Drug: SAGE-217; Placebo · For: Depression, Postpartum
Sites: Scottsdale, Arizona; Bentonville, Arkansas; Anaheim, California · 82 sites in all
- A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive DisorderPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT03000530 · 102 participants · Start Dec 7, 2016 · Primary completion Oct 4, 2017
Drug: SAGE-217; Placebo · For: Major Depression
Sites: Garden Grove, California; Orlando, Florida; Atlanta, Georgia · 8 sites in all
- A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaPivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT03771664 · 87 participants · Start Feb 4, 2019 · Primary completion Dec 20, 2019
Drug: SAGE-217; Placebo · For: Major Depressive Disorder; Insomnia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Garden Grove, California · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- somnolence637
- dizziness368
- fatigue299
- anxiety151
- sedation150
- feeling abnormal139
- suicidal ideation112
- tremor106
- feeling drunk91
- depression86
- nausea79
- memory impairment74
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 379 |
| 2025 | 753 |
| 2026 | 807 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zurzuvae (Zuranolone)
2024 spending
$544K
Beneficiaries
34
34 claims
Per beneficiary
$16,013
$571.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $544,445 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. · Am J Psychiatry 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. · JAMA Psychiatry 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies.
Oliveira JA, Eskandar K, Freitas MAA, et al. · Rev Bras Ginecol Obstet 2024 · Systematic Review, Meta-Analysis
- Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM, Citrome L, Huang MY, et al. · J Clin Psychiatry 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH, Lasser R, Nandy I, et al. · J Clin Psychiatry 2023 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV, Aaronson ST, Mathew SJ, et al. · Neuropsychopharmacology 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.